A new article from ACP is designed to help primary care physicians address barriers in transgender medical care.
To address barriers in transgender medical care, the ACP published an article as part of a special series titled “In the Clinic” to help primary care physicians understand medical issues specific to transgender patients.
Studies estimate that 0.6% of U.S. adults, or 1.4 million persons, are transgender.
“Barriers to accessing appropriate and culturally competent care contribute to health disparities in transgender persons, such as increased rates of certain types of cancer, substance abuse, mental health conditions, infections, and chronic diseases.,” the authors Joshua D. Safer, MD, of Mount Sinai Health System and Icahn School of Medicine, and Vin Tangpricha, MD, PhD, of Emory University School of Medicine and the Atlanta VA Medical Center, wrote.
Two major guidelines are mentioned by the authors in the special series, published in the Annals of Internal Medicine: The World Professional Association for Transgender Health’s Standards of Care (SOC) for the Health of Transsexual, Transgender, and Gender Nonconforming People and the Endocrine Society’s Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline.
Related: Studies Suggest ACA Helps with Healthcare Disparities
The authors advise clinicians to watch for signs and symptoms of depression, anxiety, and suicidality due to the higher rates of these conditions within the transgender population.
“The basic idea of this practical information is that a physician can make the diagnosis of gender dysphoria with adequate experience and training and initiate and monitor hormone therapy,” Tangpricha tells Managed Healthcare Executive.
“Treatment for people with gender dysphoria and gender non-conformity is medically necessary and should be covered under most medical benefits. Transgender and gender non-conforming people have effective medical and surgical options that shouldn't be denied because of differences in gender expression.”
There are four takeaways for healthcare executives, according to Tangpricha:
Medicaid Cuts Remain Center Stage as Experts Address Industry Challenges
March 28th 2025In a recent conversation with Jennifer McGuigan Babcock, senior vice president for Medicaid policy at the Association for Community Affiliated Plans (ACAP), and Gabe Scott, a partner at K&L Gates Health Care Group, the two discussed efforts to protect Medicaid’s role in the healthcare system and the consequences of the budget cuts announced in February.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More